{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epithelial+Tumors%2C+Malignant&page=3",
    "query": {
      "condition": "Epithelial Tumors, Malignant",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 12641,
    "total_pages": 1265,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epithelial+Tumors%2C+Malignant&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epithelial+Tumors%2C+Malignant&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T07:02:26.972Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03869190",
      "title": "Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Enfortumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Magrolimab (Hu5F9-G4)",
          "type": "DRUG"
        },
        {
          "name": "Tiragolumab",
          "type": "DRUG"
        },
        {
          "name": "Sacituzumab Govitecan",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 272,
      "start_date": "2019-06-01",
      "completion_date": "2025-12-22",
      "has_results": true,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-07T07:02:26.972Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03869190"
    },
    {
      "nct_id": "NCT00968968",
      "title": "Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Lapatinib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 37,
      "start_date": "2010-01-20",
      "completion_date": "2018-03-30",
      "has_results": true,
      "last_update_posted_date": "2019-06-10",
      "last_synced_at": "2026-10-07T07:02:26.972Z",
      "location_count": 112,
      "location_summary": "Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 93 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00968968"
    },
    {
      "nct_id": "NCT00003297",
      "title": "Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "1997-12",
      "completion_date": "2001-01",
      "has_results": false,
      "last_update_posted_date": "2011-03-24",
      "last_synced_at": "2026-10-07T07:02:26.972Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003297"
    },
    {
      "nct_id": "NCT01088789",
      "title": "Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide Pill",
          "type": "DRUG"
        },
        {
          "name": "GVAX Pancreas Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2010-04-20",
      "completion_date": "2026-08",
      "has_results": true,
      "last_update_posted_date": "2025-08-26",
      "last_synced_at": "2026-10-07T07:02:26.972Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01088789"
    },
    {
      "nct_id": "NCT07265674",
      "title": "A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Biliary Tract Cancer",
        "Biliary Tract Cancer (BTC)"
      ],
      "interventions": [
        {
          "name": "Nanvuranlat",
          "type": "DRUG"
        },
        {
          "name": "Physician's Best Choice",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "J-Pharma Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 480,
      "start_date": "2026-05-11",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-07T07:02:26.972Z",
      "location_count": 18,
      "location_summary": "Duarte, California • Orange, California • Santa Monica, California + 15 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Zion",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07265674"
    },
    {
      "nct_id": "NCT03463889",
      "title": "Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Gallium Ga 68-labeled PSMA-11",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography (PET)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2018-03-19",
      "completion_date": "2020-10-31",
      "has_results": true,
      "last_update_posted_date": "2021-06-29",
      "last_synced_at": "2026-10-07T07:02:26.972Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03463889"
    },
    {
      "nct_id": "NCT04684368",
      "title": "A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Central Nervous System Nongerminomatous Germ Cell Tumor",
        "Choriocarcinoma",
        "Embryonal Carcinoma",
        "Immature Teratoma",
        "Malignant Teratoma",
        "Mixed Germ Cell Tumor",
        "Pineal Region Germ Cell Tumor",
        "Pineal Region Immature Teratoma",
        "Pineal Region Yolk Sac Tumor",
        "Suprasellar Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Second-Look Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "3 Years to 29 Years"
      },
      "enrollment_count": 160,
      "start_date": "2021-07-13",
      "completion_date": "2029-12-21",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-07T07:02:26.972Z",
      "location_count": 152,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 120 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04684368"
    },
    {
      "nct_id": "NCT02695290",
      "title": "Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "ErbB Receptors"
      ],
      "interventions": [
        {
          "name": "Afatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2016-03-17",
      "completion_date": "2016-08-26",
      "has_results": true,
      "last_update_posted_date": "2017-09-18",
      "last_synced_at": "2026-10-07T07:02:26.972Z",
      "location_count": 1,
      "location_summary": "Fountain Valley, California",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02695290"
    },
    {
      "nct_id": "NCT00003497",
      "title": "Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IV Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Antineoplaston therapy (Atengenal + Astugenal)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Burzynski Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 9,
      "start_date": "1996-08-21",
      "completion_date": "1998-02-02",
      "has_results": false,
      "last_update_posted_date": "2018-02-05",
      "last_synced_at": "2026-10-07T07:02:26.972Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003497"
    },
    {
      "nct_id": "NCT00245050",
      "title": "Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer",
        "Drug/Agent Toxicity by Tissue/Organ",
        "Endometrial Cancer",
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "pyridoxine hydrochloride",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin HCL liposome",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 34,
      "start_date": "2004-04",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2011-12-30",
      "last_synced_at": "2026-10-07T07:02:26.972Z",
      "location_count": 8,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00245050"
    }
  ]
}